The FDA has extended the review period for Bristol Myers Squibb Co's BMY supplemental application for Reblozyl (luspatercept-aamt) for anemia in adults with non-transfusion-dependent (NTD) beta-thalassemia.
- The agency has pushed the decision to June 27 from March 27, granted earlier under priority review.
- The application was based on results from the pivotal Phase 2 BEYOND study evaluating Reblozyl plus best supportive care.
- An application (Type II variation) is also under review by the European Medicines Agency.
- Reblozyl is currently approved to address transfusion-dependent anemia-associated beta-thalassemia and lower-risk myelodysplastic syndromes failing an erythropoietin-stimulating agent (ESA) and requiring red blood cell transfusions.
- Separately, the Japanese regulatory authority has accepted the supplemental application for Breyanzi (lisocabtagene maraleucel) for the second-line treatment of relapsed or refractory (R/R) large B-cell lymphoma (LBCL).
- Price Action: BMY shares are closed 0.11% higher at $72.50 during after-hours trading on Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.